New monthly shot for schizophrenia enters early human testing

NCT ID NCT07484204

Not yet recruiting Disease control Sponsor: Anxo Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This early-stage trial is testing a long-acting injectable form of the drug cariprazine, called AX251, in 48 adults with stable schizophrenia. The study aims to see how the drug moves through the body and whether it is safe when given as a single shot at different doses. If results are promising, it could lead to a more convenient treatment option that requires fewer doses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cariprazine (long-acting injectable)
What this could lead to: If successful, this could lead to a longer-lasting treatment option for schizophrenia, potentially reducing the need for daily pills.
What could go wrong: This is a very early Phase 1 study with only 48 participants, so safety and effectiveness are not yet known. The drug may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

DHS Multispeciality Hospital

Ahmedabad, India
Divine Multispeciality Hospital

Gandhinagar, India
Health Hospital

Ahmedabad, India
Ratandeep Multispeciality Hospital

Nagar, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.